Pharsight

1. List of Amvuttra drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10131907	ALNYLAM PHARMS INC	Glycoconjugates of RNA interference agents	Aug, 2028 (5 years from now)
US8828956	ALNYLAM PHARMS INC	Carbohydrate conjugates as delivery agents for oligonucleotides	Dec, 2028 (5 years from now)
US9370581	ALNYLAM PHARMS INC	Carbohydrate conjugates as delivery agents for oligonucleotides	Dec, 2028 (5 years from now)
US10806791	ALNYLAM PHARMS INC	Carbohydrate conjugates as delivery agents for oligonucleotides	Dec, 2028 (5 years from now)
US8106022	ALNYLAM PHARMS INC	Carbohydrate conjugates as delivery agents for oligonucleotides	Dec, 2029 (6 years from now)
US10570391	ALNYLAM PHARMS INC	RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases	Nov, 2032 (9 years from now)
US9399775	ALNYLAM PHARMS INC	RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases	Nov, 2032 (9 years from now)
US11401517	ALNYLAM PHARMS INC	Modified double-stranded RNA agents	Aug, 2035 (12 years from now)
US10612024	ALNYLAM PHARMS INC	Modified double-stranded RNA agents	Aug, 2035 (12 years from now)
US11286486	ALNYLAM PHARMS INC	Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases	Jul, 2036 (13 years from now)
US10683501	ALNYLAM PHARMS INC	Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases	Jul, 2036 (13 years from now)
US10208307	ALNYLAM PHARMS INC	Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases	Jul, 2036 (13 years from now)
CN102006890A	ALNYLAM PHARMS INC	Targeting Lipid	Oct, 2015 (7 years ago)
EP3156077B1	ALNYLAM PHARMS INC	Targeting Lipids	Dec, 2028 (5 years from now)
EP2231195B1	ALNYLAM PHARMS INC	Targeting Lipids	Dec, 2028 (5 years from now)
EP2231194B1	ALNYLAM PHARMS INC	Folate-Irna Conjugates	Dec, 2028 (5 years from now)
EP2231195A2	ALNYLAM PHARMS INC	Targeting Lipids	Dec, 2028 (5 years from now)
EP3156077A1	ALNYLAM PHARMS INC	Targeting Lipids	Dec, 2028 (5 years from now)
EP2231194A2	ALNYLAM PHARMS INC	Folate-Irna Conjugates	Dec, 2028 (5 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jun 13, 2027

Drugs and Companies using VUTRISIRAN ingredient

NCE-1 date: June, 2026

Market Authorisation Date: 13 June, 2022

Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
25MG/0.5ML (25MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription

2. List of Baxdela drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9539250	MELINTA	Salt and crystalline forms thereof of a drug	Oct, 2025 (2 years from now)
US8273892	MELINTA	Salt and crystalline forms thereof of a drug	Aug, 2026 (3 years from now)
US8871938	MELINTA	Process for making quinolone compounds	Sep, 2029 (6 years from now)
USRE46617	MELINTA	Process for making quinolone compounds	Dec, 2029 (6 years from now)
US7728143	MELINTA	Salt and crystalline forms thereof of a drug	Jun, 2031 (8 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8648093	MELINTA	Salt and crystalline forms thereof of a drug	Oct, 2025 (2 years from now)
US8969569	MELINTA	Salt and crystalline forms thereof of a drug	Oct, 2025 (2 years from now)
US8252813	MELINTA	Salt and crystalline forms thereof of a drug	Oct, 2026 (3 years from now)
US9750822	MELINTA	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (6 years from now)
US8410077	MELINTA	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (6 years from now)
US9200088	MELINTA	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (6 years from now)
US7635773	MELINTA	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (6 years from now)
US9493582	MELINTA	Alkylated cyclodextrin compositions and processes for preparing and using the same	Feb, 2033 (10 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jun 19, 2022
New Indication (I)	Oct 24, 2022
Generating Antibiotic Incentives Now (GAIN)	Jun 19, 2027

Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient

NCE-1 date: June, 2026

Market Authorisation Date: 19 June, 2017

Treatment: Treatment of acute bacterial skin and skin structure infections caused by designated susceptible bacteria in adults

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
EQ 300MG BASE/VIAL	POWDER;INTRAVENOUS	Prescription

3. List of Bludigo drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11499050	PROVEPHARM SAS	NA	Dec, 2037 (14 years from now)
US10927258	PROVEPHARM SAS	Process for the preparation of Indigotindisulfonate sodium (indigo carmine)	Dec, 2037 (14 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jul 8, 2027

Drugs and Companies using INDIGOTINDISULFONATE SODIUM ingredient

NCE-1 date: July, 2026

Market Authorisation Date: 08 July, 2022

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
40MG/5ML (8MG/ML)	SOLUTION;INTRAVENOUS	Prescription

4. List of Camzyos drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9181200	BRISTOL	Pyrimidinedione compounds	Jun, 2034 (11 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9585883	BRISTOL	Pyrimidinedione compounds	Jun, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Apr 28, 2027

Drugs and Companies using MAVACAMTEN ingredient

NCE-1 date: April, 2026

Market Authorisation Date: 28 April, 2022

Treatment: Treatment of adults with symptomatic new york heart association (nyha) class ii-iii obstructive hypertrophic cardiomyopathy (hcm) to improve functional capacity and symptoms

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
2.5MG	CAPSULE;ORAL	Prescription
5MG	CAPSULE;ORAL	Prescription
10MG	CAPSULE;ORAL	Prescription
15MG	CAPSULE;ORAL	Prescription

5. List of Cibinqo drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9545405	PFIZER	Pyrrolo[2,3-D]pyrimidine derivatives	Feb, 2034 (11 years from now)
US9035074	PFIZER	Pyrrolo[2,3-D]pyrimidine derivatives	Feb, 2034 (11 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549929	PFIZER	Pyrrolo[2,3-D]pyrimidine derivatives	Feb, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jan 14, 2027

Drugs and Companies using ABROCITINIB ingredient

NCE-1 date: January, 2026

Market Authorisation Date: 14 January, 2022

Treatment: Treatment of adults with refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products or when use of those therapies is inadvisable

Dosage: TABLET;ORAL

Strength	Dosage	Availability
50MG	TABLET;ORAL	Prescription
100MG	TABLET;ORAL	Prescription
200MG	TABLET;ORAL	Prescription

6. List of Cresemba drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6812238	ASTELLAS	N-substituted carbamoyloxyalkyl-azolium derivatives	Oct, 2025 (2 years from now)
US10812238	ASTELLAS	Configurable reference signals	Oct, 2025 (2 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10603280	ASTELLAS	Active ingredient containing stabilised solid medicinal forms and methods for the production thereof	Sep, 2027 (4 years from now)
US10206879	ASTELLAS	Active ingredient containing stabilised solid forms and method for the production thereof	Sep, 2027 (4 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Mar 6, 2022
New Chemical Entity Exclusivity (NCE)	Mar 6, 2020
Generating Antibiotic Incentives Now (GAIN)	Mar 6, 2027

Drugs and Companies using ISAVUCONAZONIUM SULFATE ingredient

NCE-1 date: March, 2026

Market Authorisation Date: 06 March, 2015

Treatment: NA

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
372MG	POWDER;INTRAVENOUS	Prescription

7. List of Elucirem drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8114863	GUERBET	Compounds comprising short aminoalcohol chains and metal complexes for medical imaging	Sep, 2028 (5 years from now)
US10973934	GUERBET	Gadolinium bearing PCTA-based contrast agents	Aug, 2039 (16 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Sep 21, 2027

Drugs and Companies using GADOPICLENOL ingredient

NCE-1 date: September, 2026

Market Authorisation Date: 21 September, 2022

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
1.4553GM/3ML (485.1MG/ML)	SOLUTION;INTRAVENOUS	Prescription
3.63825GM/7.5ML (485.1MG/ML)	SOLUTION;INTRAVENOUS	Prescription
4.851GM/10ML (485.1MG/ML)	SOLUTION;INTRAVENOUS	Prescription
7.2765GM/15ML (485.1MG/ML)	SOLUTION;INTRAVENOUS	Prescription
14.553GM/30ML (485.1MG/ML)	SOLUTION;INTRAVENOUS	Prescription
24.255GM/50ML (485.1MG/ML)	SOLUTION;INTRAVENOUS	Prescription
48.51GM/100ML (485.1MG/ML)	SOLUTION;INTRAVENOUS	Prescription

8. List of Lytgobi drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9108973	TAIHO ONCOLOGY	3,5-disubstituted alkynylbenzene compound and salt thereof	Feb, 2033 (10 years from now)
US10434103	TAIHO ONCOLOGY	Crystal of 3,5-disubstituted benzene alkynyl compound	Mar, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Sep 30, 2027

Drugs and Companies using FUTIBATINIB ingredient

NCE-1 date: September, 2026

Market Authorisation Date: 30 September, 2022

Treatment: Method of treating intrahepatic cholangiocarcinoma

Dosage: TABLET;ORAL

Strength	Dosage	Availability
4MG	TABLET;ORAL	Prescription

9. List of Mounjaro drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9474780	ELI LILLY AND CO	GIP and GLP-1 co-agonist compounds	Jan, 2036 (12 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8734394	ELI LILLY AND CO	Automatic injection device with delay mechanism including dual functioning biasing member	Feb, 2031 (8 years from now)
US9402957	ELI LILLY AND CO	Automatic injection device with delay mechanism including dual functioning biasing member	Jun, 2031 (8 years from now)
US11357820	ELI LILLY AND CO	GIP/GLP1 agonist compositions	Jun, 2039 (16 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	May 13, 2027

Drugs and Companies using TIRZEPATIDE ingredient

NCE-1 date: May, 2026

Market Authorisation Date: 13 May, 2022

Treatment: Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
2.5MG/0.5ML (2.5MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription
5MG/0.5ML (5MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription
7.5MG/0.5ML (7.5MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription
10MG/0.5ML (10MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription
12.5MG/0.5ML (12.5MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription
15MG/0.5ML (15MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription

10. List of Omlonti drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8648097	SANTEN	Pyridylaminoacetic acid compound	Oct, 2029 (6 years from now)
US10774072	SANTEN	Crystal of N-substituted sulfonamide compound	Jun, 2035 (12 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8685986	SANTEN	Medical composition for treatment or prophylaxis of glaucoma	Oct, 2029 (6 years from now)
US10702511	SANTEN	Pharmaceutical formulations comprising a pyridylaminoacetic acid compound	Jan, 2035 (11 years from now)
US10765750	SANTEN	Pharmaceutical composition containing pyridylaminoacetic acid compound	Jan, 2035 (11 years from now)
US10179127	SANTEN	Pharmaceutical formulations comprising a pyridylaminoacetic acid compound	Jan, 2035 (11 years from now)
US11197849	SANTEN	Pharmaceutical formulations comprising a pyridylaminoacetic acid compound	Jan, 2035 (11 years from now)
US9415038	SANTEN	Pharmaceutical formulations comprising a pyridylaminoacetic acid compound	Jan, 2035 (11 years from now)
USRE48183	SANTEN	Pharmaceutical formulations comprising a pyridylaminoacetic acid compound	Jan, 2035 (11 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Sep 22, 2027

Drugs and Companies using OMIDENEPAG ISOPROPYL ingredient

NCE-1 date: September, 2026

Market Authorisation Date: 22 September, 2022

Treatment: Method of treating open-angle glaucoma or ocular hypertension in patients

Dosage: SOLUTION;OPHTHALMIC

Strength	Dosage	Availability
0.002%	SOLUTION;OPHTHALMIC	Prescription

11. List of Pluvicto drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10406240	AAA USA NOVARTIS	PSMA binding ligand-linker conjugates and methods for using	Aug, 2028 (5 years from now)
US11318121	AAA USA NOVARTIS	PSMA binding ligand-linker conjugates and methods for using	Aug, 2028 (5 years from now)
US10398791	AAA USA NOVARTIS	Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer	Oct, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Mar 23, 2027

Drugs and Companies using LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN ingredient

NCE-1 date: March, 2026

Market Authorisation Date: 23 March, 2022

Treatment: For treatment of adult patients with prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with androgen receptor (ar) pathway inhibition and taxane-based chemotherapy

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
27mCi/ML	SOLUTION;INTRAVENOUS	Prescription

12. List of Pyrukynd drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8785450	AGIOS PHARMS INC	Therapeutic compounds and compositions	Feb, 2031 (8 years from now)
US11254652	AGIOS PHARMS INC	Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide	Nov, 2038 (15 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10632114	AGIOS PHARMS INC	Pyruvate kinase activators for use in therapy	May, 2032 (9 years from now)
US9682080	AGIOS PHARMS INC	Pyruvate kinase activators for use in therapy	May, 2032 (9 years from now)
US9980961	AGIOS PHARMS INC	Pyruvate kinase activators for use in therapy	May, 2032 (9 years from now)
US9193701	AGIOS PHARMS INC	Pyruvate kinase activators for use in therapy	Oct, 2032 (9 years from now)
US11234976	AGIOS PHARMS INC	Methods of using pyruvate kinase activators	Oct, 2038 (15 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Feb 17, 2027

Drugs and Companies using MITAPIVAT SULFATE ingredient

NCE-1 date: February, 2026

Market Authorisation Date: 17 February, 2022

Treatment: Method for increasing the lifetime of red blood cells (rbcs) for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency; Method of using a pyruvate kinase activator for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency; Method of using a pyruvate kinase activator for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency by administering a daily dose of 10mg to 100mg

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 5MG BASE	TABLET;ORAL	Prescription
EQ 20MG BASE	TABLET;ORAL	Prescription
EQ 50MG BASE	TABLET;ORAL	Prescription

13. List of Quviviq drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9732075	IDORSIA	Benzimidazole-proline derivatives	Jun, 2033 (10 years from now)
US9790208	IDORSIA	Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist	Dec, 2034 (11 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10023560	IDORSIA	Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist	Dec, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Apr 7, 2027

Drugs and Companies using DARIDOREXANT HYDROCHLORIDE ingredient

NCE-1 date: April, 2026

Market Authorisation Date: 07 April, 2022

Treatment: Treatment of insomnia

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 25MG BASE	TABLET;ORAL	Prescription
EQ 50MG BASE	TABLET;ORAL	Prescription

14. List of Relyvrio drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9872865	AMYLYX	Compositions for improving cell viability and methods of use thereof	Dec, 2033 (10 years from now)
US11071742	AMYLYX	Compositions for improving cell viability and methods of use thereof	Dec, 2033 (10 years from now)
US10251896	AMYLYX	Compositions for improving cell viability and methods of use thereof	Dec, 2033 (10 years from now)
US10857162	AMYLYX	Compositions for improving cell viability and methods of use thereof	Dec, 2033 (10 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Sep 29, 2027

Drugs and Companies using SODIUM PHENYLBUTYRATE; TAURURSODIOL ingredient

NCE-1 date: September, 2026

Market Authorisation Date: 29 September, 2022

Treatment: Treatment of amyotrophic lateral sclerosis (als) in adults

Dosage: FOR SUSPENSION;ORAL

Strength	Dosage	Availability
3GM/PACKET; 1GM/PACKET	FOR SUSPENSION;ORAL	Prescription

15. List of Solosec drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10849884	LUPIN	Secnidazole for use in the treatment of bacterial vaginosis	Sep, 2035 (12 years from now)
US11324721	LUPIN	Secnidazole for use in the treatment of trichomoniasis	Sep, 2035 (12 years from now)
US10857133	LUPIN	Secnidazole for use in the treatment of bacterial vaginosis	Sep, 2035 (12 years from now)
US10682338	LUPIN	Secnidazole for use in the treatment of bacterial vaginosis	Sep, 2035 (12 years from now)
US11000508	LUPIN	Secnidazole for use in the treatment of trichomoniasis	Sep, 2035 (12 years from now)
US11020377	LUPIN	Secnidazole for use in the treatment of bacterial vaginosis	Sep, 2035 (12 years from now)
US11000507	LUPIN	Secnidazole for use in the treatment of bacterial vaginosis	Sep, 2035 (12 years from now)
US10335390	LUPIN	Secnidazole for use in the treatment of bacterial vaginosis	Sep, 2035 (12 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Sep 15, 2022
New Indication (I)	Jun 30, 2024
New Patient Population (NPP)	Jan 26, 2025
Generating Antibiotic Incentives Now (GAIN)	Sep 15, 2027

Drugs and Companies using SECNIDAZOLE ingredient

NCE-1 date: September, 2026

Market Authorisation Date: 15 September, 2017

Treatment: Treatment of bacterial vaginosis in female patients 12 years of age and older; Treatment of trichomoniasis in patients 12 years of age and older; Treatment of trichomoniasis in adults; Treatment of bacterial vaginosis in adult women

Dosage: GRANULE;ORAL

Strength	Dosage	Availability
2GM/PACKET	GRANULE;ORAL	Prescription

16. List of Sotyktu drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE47929	BRISTOL	Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses	Nov, 2033 (10 years from now)
US10000480	BRISTOL	Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses	Nov, 2033 (10 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11021475	BRISTOL	Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses	Nov, 2033 (10 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Sep 9, 2027

Drugs and Companies using DEUCRAVACITINIB ingredient

NCE-1 date: September, 2026

Market Authorisation Date: 09 September, 2022

Treatment: Treatment of moderate-to-severe plaque psoriasis in adults who are canididates for systemic therapy or phototherapy

Dosage: TABLET;ORAL

Strength	Dosage	Availability
6MG	TABLET;ORAL	Prescription

17. List of Vabomere drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8680136	REMPEX	Cyclic boronic acid ester derivatives and therapeutic uses thereof	Aug, 2031 (8 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11007206	REMPEX	Cyclic boronic acid ester derivatives and therapeutic uses thereof	Aug, 2031 (8 years from now)
US9694025	REMPEX	Cyclic boronic acid ester derivatives and therapeutic uses thereof	Aug, 2031 (8 years from now)
US10183034	REMPEX	Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives	Aug, 2031 (8 years from now)
US10172874	REMPEX	Pharmaceutical compositions comprising cyclic boronic acid ester derivatives	Aug, 2031 (8 years from now)
US10561675	REMPEX	Cyclic boronic acid ester derivatives and therapeutic uses thereof	Aug, 2031 (8 years from now)
US11376237	REMPEX	Methods of treating bacterial infections	Apr, 2039 (16 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Aug 29, 2022
Generating Antibiotic Incentives Now (GAIN)	Aug 29, 2027

Drugs and Companies using MEROPENEM; VABORBACTAM ingredient

NCE-1 date: August, 2026

Market Authorisation Date: 29 August, 2017

Treatment: Treatment of complicated urinary tract infections (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli, klebsiella pneumonia, enterobacter cloacae species complex with meropenem & vaborbactam as specified; Treatment of patients 18 years of age and older with complicated urinary tract infections caused by susceptible microorganisms; Treatment of complicated urinary tract infection (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli, klebsiella pneumonia, and enterobacter cloacae species complex; Treatment of complicated urinary tract infections (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli,klebsiella pneumonia,enterobacter cloacae species complex with meropenem & vaborbactam as specified

Dosage: POWDER;INTRAVENOUS

18. List of Vonjo drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8153632	CTI BIOPHARMA CORP	Oxygen linked pyrimidine derivatives	Jan, 2029 (5 years from now)
US8980873	CTI BIOPHARMA CORP	11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt	Mar, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9573964	CTI BIOPHARMA CORP	Oxygen linked pyrimidine derivatives	May, 2028 (5 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Feb 28, 2027

Drugs and Companies using PACRITINIB CITRATE ingredient

NCE-1 date: February, 2026

Market Authorisation Date: 28 February, 2022

Treatment: Use of pacritinib for inhibiting janus associated kinase 2(jak2); Treatment of myelofibrosis with pacritinib

Dosage: CAPSULE;ORAL

19. List of Vtama drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10647649	DERMAVANT SCI	Process for preparing tapinarof	Nov, 2038 (15 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11458108	DERMAVANT SCI	NA	May, 2036 (13 years from now)
US10195160	DERMAVANT SCI	Topical pharmaceutical compositions	May, 2036 (13 years from now)
US10426743	DERMAVANT SCI	Topical pharmaceutical compositions	May, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	May 23, 2027

Drugs and Companies using TAPINAROF ingredient

NCE-1 date: May, 2026

Market Authorisation Date: 23 May, 2022

Treatment: Topical treatment of plaque psoriasis in adults

Dosage: CREAM;TOPICAL

20. List of Ztalmy drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7858609	MARINUS	Solid ganaxolone formulations and methods for the making and use thereof	Nov, 2026 (3 years from now)
US8022054	MARINUS	Liquid ganaxolone formulations and methods for the making and use thereof	Nov, 2026 (3 years from now)
US8318714	MARINUS	Liquid ganaxolone formulations and methods for the making and use thereof	Nov, 2026 (3 years from now)
US8618087	MARINUS	Solid ganaxolone formulations and methods for the making and use thereof	Nov, 2026 (3 years from now)
US9056116	MARINUS	Liquid ganaxolone formulations and methods for the making and use thereof	Nov, 2026 (3 years from now)
US8367651	MARINUS	Solid ganaxolone formulations and methods for the making and use thereof	Nov, 2026 (3 years from now)
US9029355	MARINUS	Solid ganaxolone compositions and methods for the making and use thereof	Nov, 2026 (3 years from now)
US10603308	MARINUS	Methods and compositions for treatment of epileptic disorders	Aug, 2037 (14 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jun 1, 2027

Drugs and Companies using GANAXOLONE ingredient

NCE-1 date: June, 2026

Market Authorisation Date: 01 June, 2022

Treatment: Treatment of seizures associated with cyclin-dependent kinase-like 5 (cdkl5) deficiency disorder (cdd) in patients 2 years of age and older

Dosage: SUSPENSION;ORAL